Kim, Jihun <br/><br/>
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.  [electronic resource] 

 -  The Journal of clinical investigation  Dec 2014 
 - 5145-58 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1558-8238 
<br/><br/><label>Standard No.: </label>10.1172/JCI75200  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--genetics<br/>Esophageal Neoplasms--diet therapy<br/>Female<br/>Gene Amplification--drug effects<br/>Humans<br/>Male<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Receptor, ErbB-2--genetics<br/>Stomach Neoplasms--drug therapy<br/>Trastuzumab